Postherpetic Neuralgia (PHN) Market: Major Trends Reshaping the Future of the Industry

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Postherpetic Neuralgia (PHN) Industry Market Size Be by 2025?
The market for postherpetic neuralgia (phn) has witnessed significant growth lately. The market, which was worth $0.72 billion in 2024, is projected to increase to $0.77 billion by 2025, showcasing a compound annual growth rate (CAGR) of 7.0%. The expansion during the previous periods is linked to a higher occurrence of herpes zoster infections, an increasing older population, enhanced understanding among patients and healthcare providers, heightened demand for effective solutions to manage neuropathic pain, and escalated healthcare spending.

What's the Long-Term Growth Forecast for the Postherpetic Neuralgia (PHN) Market Size Through 2029?
Over the next several years, the market for postherpetic neuralgia (phn) is predicted to experience substantial growth, reaching an estimated $0.99 billion by 2029 with a compound annual growth rate (CAGR) of 6.6%. This growth during the forecast period is likely due to the increased utilization of antiviral drugs and vaccines, a rapid increase in chronic pain disorders, a growing acceptance of innovative drug delivery systems, escalating clinical trial numbers and investments in research and development, and a rise in regulatory approvals for advanced therapeutics. Noteworthy trends for the forecast period involve progress in neuropathic pain studies, advancements in drug delivery technologies, diagnostic tools enhanced by technology, the incorporation of artificial intelligence in clinical trials, and advancements in non-opioid pain relief treatments.

View the full report here:
https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

What Are the Key Growth Drivers Fueling the Postherpetic Neuralgia (PHN) Market Expansion?
The surge in chronic pain conditions is anticipated to fuel the expansion of the postherpetic neuralgia (PHN) market. Chronic pain, which persists or reoccurs for more than three months, often extends past the normal course of a disease or injury, impacting an individual's daily activities and life quality. The spike in chronic pain conditions can be attributed to the aging demographic, as senior individuals are particularly susceptible to degenerative diseases like arthritis and neuropathy, which cause long-lasting pain. Postherpetic neuralgia aids in the research of chronic pain as it offers a comprehensive model to analyze nerve-associated pain procedures and assess prolonged treatment strategies. For instance, in January 2024, a report issued by the Office for Health Improvement and Disparities, a UK governmental agency, asserted that around 18.4% of individuals aged 16 and above had a long-term musculoskeletal (MSK) condition in 2023, an increase from 17.6% in 2022. Thus, the mounting incidence of chronic pain conditions is driving the expansion of the postherpetic neuralgia (PHN) market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

What Are the Key Trends Driving Postherpetic Neuralgia (PHN) Market Growth?
Main businesses active in the postherpetic neuralgia (PHN) sector are working towards securing regulatory approvals with an aim to enhance their product range, gain a competitive edge, and meet substantial unfulfilled clinical demands for more efficient and tolerable treatment options. These regulatory approvals represent the official authorizations issued by governmental health departments, enabling a medication or therapy to be legally marketed and utilized for a specific health condition. To illustrate, in February 2023, Zydus Lifesciences Ltd., a pharmaceutical firm based in India, secured the final approval from the United States Food and Drug Administration to produce and market one-a-day generic Gabapentin Tablets in 300 mg and 600 mg strengths, which are designed for the treatment of postherpetic neuralgia (PHN). These gabapentin tablets are meant for the therapy of PHN, a neuropathic pain type derived from nerve damage due to the varicella-zoster virus's reactivation. Regarding PHN, the typical dosage initiation is at 300 mg on day one, escalates to 600 mg (300 mg twice in a day) on day two, and 900 mg (300 mg three times daily) on day three, with the titration going as high as to 1800 mg per day (600 mg thrice daily) depending on the requirement for pain alleviation.

How Is the Postherpetic Neuralgia (PHN) Market Segmented?
The postherpetic neuralgia (PHN) market covered in this report is segmented -

1) By Type: Patches, Drugs, Opioids
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End Users

Subsegments:
1) By Patches: Transdermal Drug Delivery Patches, Nicotine Patches, Hormone Replacement Therapy Patches, Analgesic Patches, Orthopedic Support Patches
2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs
3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24664&type=smp

Which Companies Are Leading the Charge in Postherpetic Neuralgia (PHN) Market Innovation?
Major companies operating in the postherpetic neuralgia (PHN) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Lexicon Pharmaceuticals Inc., Oxford cannabi*noid Technologies Holdings plc, Teikoku Pharma USA Inc., Acasti Pharma Inc., Flexion Therapeutics Inc., Haisco Pharmaceutical Group Co. Ltd., Shanghai SIMR Biotechnology Co. Ltd.

Which Regions Are Leading the Global Postherpetic Neuralgia (PHN) Market in Revenue?
North America was the largest region in the postherpetic neuralgia (PHN) market in 2024. The regions covered in the postherpetic neuralgia (PHN) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report to*day:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24664

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.